Scanxiety isn’t just about CTs, MRIs, or PET scans. It’s also about waiting for biomarker blood tests, ctDNA monitoring, or tumor markers. It’s the unease that creeps in days before the appointment, the tension of watching the doctor’s face as they read your chart, the overwhelming silence that follows when results are pending.
Scanxiety: A Silent Struggle Shared by Many Patients and Caregivers Read More »
This document summarizes key clinical trial findings for Dato-DXd in non-small cell lung cancer (NSCLC), focusing on results from two studies: the Phase II TROPION-Lung05 and the Phase III TROPION-Lung01 trials. Special attention is given to the outcomes in patients with EGFR-mutated disease, including a deeper analysis of Dato-DXd’s potential role in this molecular subgroup.
UNDERSTANDING DATO-DXd CLINICAL TRIAL RESULTS IN NSCLC Read More »
The American Society of Clinical Oncology (ASCO) 2025 annual meeting, held from May 30 to June 3, 2025, featured significant clinical developments across multiple cancer treatment modalities, with particular attention to antibody-drug conjugates (ADCs), CAR-T cell therapies, and immuno-oncology agents.
ASCO 2025 Highlights: Key Clinical Developments and Regulatory Updates Read More »
This comprehensive guide will walk you through the essential steps to take immediately following your diagnosis, helping you move from initial shock to informed action while maintaining hope and agency throughout your cancer journey.
What to Expect After a Cancer Diagnosis Read More »
Some experts champion soy for its potential protective effects, while others raise concerns about its influence on hormone-related cancers, especially breast cancer. This post explores both perspectives, reviews the latest research, and offers practical nutrition tips for cancer patients considering soy in their diets.
Nutrition Tips for Cancer Patients: The Soybean Debate Read More »
Prostate cancer remains one of the most common cancers affecting men worldwide, with the American Cancer Society estimating about 299,010 new cases and 35,250 deaths in the United States alone in 2024.
Unseen Until It’s Too Late: Understanding the Diagnostic Challenges of Prostate Cancer Read More »
Circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing are rapidly transforming the landscape of cancer care. By offering a noninvasive window into the molecular status of a patient’s disease, these technologies are enabling earlier detection of recurrence, more precise monitoring of treatment response, and increasingly personalized therapeutic strategies.
The Role of ctDNA/MRD Testing in Cancer: Promise, Practice, and Pitfalls Read More »
The past two months have brought exciting progress in cancer care, with new therapies offering hope for better outcomes and fewer side effects. Below, we break down the latest updates in simple terms, focusing on how these advances might help patients and families navigate treatment decisions.
Cancer Treatment Breakthrough Updates – April / May 2025 Read More »
This blog explores these novel treatments, their efficacy in specific NSCLC populations, and their potential pathway to US approval.
Emerging NSCLC Treatments: Novel Therapies from Global Markets Awaiting US Approval Read More »
PD-1/PD-L1 inhibitors have transformed cancer care, but their immune-activating mechanisms often lead to diverse side effects requiring tailored management. By categorizing these adverse events and pairing them with evidence-based strategies, patients and clinicians can better navigate treatment challenges. Below, we explore common and rare side effects, their clinical presentations, and practical management approaches, enriched with real-world patient experiences.
Managing PD-1/PD-L1 Immunotherapy Side Effects: Strategies and Patient Insights Read More »
